Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
17/26/17	NT$54.80	-3.18%	1,38,084
16/26/16	NT$56.60	-2.92%	1,71,748
15/26/15	NT$58.30	-6.27%	3,30,904
14/26/14	NT$62.20	-2.20%	16,31,435
13/26/13	NT$63.60	+9.84%	2,68,949

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 17/07/2026			5-day change	1st Jan Change
54.80 ^TWD	-3.18%		-5.35%	-7.90%

13/07	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
14/05	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	423.52Cr 13Cr 11Cr 11Cr 9.71Cr 18Cr 1.26TCr 19Cr 125.97Cr 50Cr 616.41Cr 49Cr 48Cr 2.12TCr	P/E 2024	-31x	P/E 2025	-22.2x
Enterprise Value	680.89Cr 21Cr 18Cr 17Cr 16Cr 29Cr 2.02TCr 30Cr 202.52Cr 80Cr 990.99Cr 79Cr 77Cr 3.41TCr	EV / Sales 2024	3.48x	EV / Sales 2025	3.58x
Free-Float	53.01%	Yield 2024 *	-	Yield 2025	-

13/07	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
14/05	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/03	Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/11	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/25/12	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
17/25/17	Bionime Corporation Approves Amendment to the Article of Incorporation	CI
12/25/12	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/25/10	Bionime Sees No Impact from US Reciprocal Tariffs	MT
12/24/12	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/24/14	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
08/24/08	Bionime Corporation Announces Financial Officer Changes	CI
28/24/28	Bionime Corporation Approves Cash Dividends, Payable on August 23, 2024	CI
10/24/10	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

02/22/02	Bionime Announces the Introduction of Its Revolutionary iFree CGM for Diabetes Management Coming Soon	AQ
01/22/01	Bionime Corporation to Launch the Rightest iFree CGM, Proposed to Offer Precise and Accurate Blood Glucose Measurement and Monitoring	AQ
25/22/25	Bionime RIGHTEST iFree CGM System - An Innovative Approach to Keep Track of Every One Health	AQ
04/22/04	Bionime : Announcement of change the Globle Sales Division officer of the company.	PU
05/22/05	Bionime : Announcement of members of the first order audit committee of the Company.	PU

Bionime Corporation Share Price

Stocks

4737

TW0004737002

Medical Equipment, Supplies & Distribution

Valuation: Bionime Corporation

Chart: Bionime Corporation

Latest news : Bionime Corporation

Press Releases: Bionime Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Bionime Corporation

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-3.18%
1 week	-5.35%
Current month	-1.44%
1 month	-2.49%
3 months	-18.21%
6 months	-0.72%
Current year	-7.90%

1 week	54.8	69.9
1 month	54.8	69.9
Current year	49.75	72.9
1 year	49.75	73.9
3 years	43.14	81.92
5 years	43.14	88.92
10 years	40	88.92

Manager	Title	Age	Since
Chun Mu Huang CEO	Chief Executive Officer	-	09/07/2010
Hui Chen Chen DFI	Director of Finance/CFO	-	06/11/2017
Zhi Long Yeh CTO	Chief Tech/Sci/R&D Officer	-	07/11/2018

Director	Title	Age	Since
Chun Mu Huang CHM	Chairman	-	14/04/2003
Tai Hsiung Chiang BRD	Director/Board Member	-	17/10/2007
Chung Kai Tai BRD	Director/Board Member	-	15/05/2007

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIONIME CORPORATION	-3.18%	-5.35%	-17.43%	-21.83%	13Cr
GUARDANT HEALTH, INC.	+0.56%	-2.61%	+229.67%	+311.59%	2.07TCr
BIOMÉRIEUX	+0.41%	+4.58%	-38.29%	-21.77%	985.31Cr
LANTHEUS HOLDINGS, INC.	+2.36%	+1.85%	+46.18%	+23.10%	700.48Cr
10X GENOMICS, INC.	-1.66%	+2.36%	+251.33%	-25.86%	555.31Cr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.36%	+3.63%	-16.92%	-28.57%	523.49Cr
CARIS LIFE SCIENCES, INC.	+0.06%	-2.94%	-47.29%	-	466.14Cr
ANDON HEALTH CO., LTD.	+10.00%	+34.69%	+106.09%	+132.05%	490.06Cr
DIASORIN S.P.A.	-0.66%	+0.73%	-23.15%	-24.82%	420.41Cr
AUTOBIO DIAGNOSTICS CO., LTD.	-2.66%	+4.71%	-15.30%	-40.67%	271.71Cr
Average	+0.56%	+3.86%	+47.49%	+33.69%	649.28Cr
Weighted average by Cap.	+0.98%	+3.63%	+94.85%	+108.25%

	2024	2025
Net sales	193.37Cr 5.97Cr 5.21Cr 4.81Cr 4.44Cr 8.36Cr 574.65Cr 8.55Cr 58Cr 23Cr 281.44Cr 22Cr 22Cr 968.86Cr	183.86Cr 5.67Cr 4.96Cr 4.58Cr 4.22Cr 7.95Cr 546.38Cr 8.13Cr 55Cr 22Cr 267.59Cr 21Cr 21Cr 921.18Cr
Net income	-13Cr -39.26L -34.31L -31.66L -29.18L -55L -38Cr -56.22L -3.78Cr -1.49Cr -19Cr -1.47Cr -1.44Cr -64Cr	-18Cr -55.63L -48.62L -44.86L -41.35L -77.94L -54Cr -79.67L -5.36Cr -2.11Cr -26Cr -2.09Cr -2.04Cr -90Cr
Net Debt	278.4Cr 8.59Cr 7.51Cr 6.93Cr 6.39Cr 12Cr 827.32Cr 12Cr 83Cr 33Cr 405.19Cr 32Cr 32Cr 1.39TCr	257.37Cr 7.94Cr 6.94Cr 6.4Cr 5.9Cr 11Cr 764.82Cr 11Cr 77Cr 30Cr 374.58Cr 30Cr 29Cr 1.29TCr